The BioPharma Leaders Forum in Toronto on 12-Jun-2025 united key figures from various sectors like pharma, biotech, healthcare, academia, and consulting to pioneer cross-functional collaboration. This inaugural conference emphasized the integration of Commercial, Market Access, Governmental Affairs, Medical Affairs, Evidence Generation, Drug Discovery, and Patient Support Services to propel healthcare innovation and enhance patient outcomes.

A special acknowledgment to Jefferson Tea, PhD MBA of Agilis Health, for curating such a significant event that showcased remarkable talent diversity on stage.

Hygeia Group was privileged to participate in this groundbreaking gathering, offering valuable networking prospects and actionable insights.

Key Highlights:

(1) Canada is emerging as a robust biopharma market with the potential to excel. Companies like KYE Pharma, ODAIA and several others are poised to take advantage of this potential. Despite external complexities, Canada boasts the talent and evolving infrastructure to not only address local challenges but also influence strategies globally.

Panel discussions delved into the Policy Ripple Effects, focusing on the impact of Most Favoured Nation (MFN) and International Reference Pricing (IRP) on Canadian pharmaceutical pricing. Concerns were raised about potential losses for Canada, particularly if counter tariffs are imposed by the federal Government.

(2) Emphasizing the significance of Real World Evidence (RWE) in deriving data-driven insights throughout the Product Life Cycle via an omni-channel approach.

(3) Consensus among participants highlighted the necessity for more forums akin to the BioPharma Leaders Forum to dismantle barriers and ensure industry stakeholders prioritize patient-centric approaches amidst evolving landscapes.

Kudos to Agilis Health for hosting an exceptional conference!